Therefore, neutralizing IL-17A could recover the interaction of effector CD8+ T cells and tumor vascular endothelium via the LFA-1/ICAM-1, and also restore the NO production from endothelial cells, facilitating the infiltration of CD8+ T cells, particularly the stem-like subset, into the tumor bed. The gene discussed is ITGAL; the disease is neoplasm.